29-SEP-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     4122 369 165 87 26 7 02/06/2019 478 185
Screened at PD     1568 243 111 60 14 4      
Pre-Screened prior to PD     2527 109 47 24 11 2      
Treatment-naive     27 17 7 3 1 1      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     542 29 13 8 2 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2277 300 146 69 20 8      
Screened at PD     1337 241 119 58 17 6      
Pre-Screened prior to PD     854 38 18 7 1 0      
Treatment-naive     27 17 7 3 1 1      
After PD on a Lung_MAP Sub-Study     59 4 2 1 1 1      
 
Sub-Study Assignments (open studies only)
S1800E     458 258 125 58 17 5      
S1900G     42 10 7 4 1 1      
S1900J     18 5 1 0 0 0      
S1900K     45 23 9 3 1 1      
S1900N     4 4 4 4 1 1      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     676 139 68 32 10 2      
Initial sub-study registrations     663 138 67 31 10 2      
Subsequent sub-study registrations     13 1 1 1 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 139 114 57 29 9 2 05/22/2025 361 119
Docetaxel plus Ramucirumab Y   70 57 28 12 3 1      
Cemiplimab plus Docetaxel and Ramucirumab Y   69 57 29 17 6 1      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   44 28 6 4 1 0 0 05/05/2023 339 107
Capmatinib + Osimertinib + Ramucirumab Y   16 4 2 1 0 0      
Capmatinib + Osimertinib Y   12 2 2 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 4 2 0 0 0 0 11/19/2024 282 86
Amivantamab Hyaluronidase Y   4 2 0 0 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 30 16 6 1 0 0 08/08/2024 297 92
Tepotinib + Ramucirumab Y   21 12 5 1 0 0      
Tepotinib Y   9 4 1 0 0 0      
S1900N: AGAs: SG alone, I alone, or SG + I   117 1 1 1 1 1 0 09/22/2026 120 35
Sacituzumab Govitecan Y   1 1 1 1 1 0